GH Research price target raised to $35 from $25 at Cantor Fitzgerald

Cantor Fitzgerald raised the firm’s price target on GH Research (GHRS) to $35 from $25 and keeps an Overweight rating on the shares. GH Research is viewed as operating in a large and expanding psychedelic therapy market with significant unmet mental health need, where long-term peak sales across related treatments could reach roughly $50B, supporting a constructive demand backdrop despite ongoing uncertainty around competitive dynamics in the space, the analyst tells investors in a research note.